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Retrograde ascending aortic dissection as an early
complication of thoracic endovascular aortic repair
Judson B. Williams, MD, MHS,a,c Nicholas D. Andersen, MD,a Syamal D. Bhattacharya, MD,a
Elizabeth Scheer, MPAS, PA-C,a Jonathan P. Piccini, MD, MHS,c Richard L. McCann, MD,b and
G. Chad Hughes, MD,a Durham, NC
Objective: Retrograde ascending aortic dissection (rAAD) is a potential complication of thoracic endovascular aortic repair
(TEVAR), yet little data exist regarding its occurrence. This study examines the incidence, etiology, and outcome of this event.
Methods: A prospective institutional database was used to identify cases of acute rAAD following TEVAR from a cohort
of 309 consecutive procedures from March 2005 (date of initial Food and Drug Administration approval) to September
2010. The database was analyzed for the complication of rAAD as well as relevant patient and operative variables.
Results: The incidence of rAAD was 1.9% (6/309); all cases occurred with proximal landing zone in the ascending aorta
and/or arch (zones 0-2). All were identified in the perioperative period (range, 0-6 days) with 33% (2/6) 30-day/in-
hospital mortality. Eighty-three percent (5/6) underwent emergent repair; one patient died without repair. rAAD
patients were similar to the non-rAAD group (n 303) across pertinent variables, including age, gender, race, and device
size (all P > .1). rAAD incidence by aortic pathology was 1.0% (2/200) for aneurysm, 4.4% (4/91) for dissection, and
0% (0/18) for transection; P  .08. rAAD incidence by device was TAG (Gore) 1.0% (2/205), Talent (Medtronic) 4.7%
(2/43), and Zenith TX2 (Cook) 3.6% (2/55). rAAD incidence was observed to be higher among patients with an
ascending aortic diameter >4.0 cm (4.8% vs 0.9% for ascending diameter <4.0 cm); P  .047. Incidence was also higher
with proximal landing zone in the native ascending aorta (zone 0) 6.9% (2/29) versus 1.4% for all others (4/280); P 
.101. For patients with dissection pathology and an ascending aortic diameter>4.0 cm, 11% (3/28) suffered rAAD; with
the combination of native ascending aorta (zone 0) landing zone measuring >4.0 cm, the incidence was 25% (2/8).
Definitive diagnosis was by computed tomography angiography (n  1), intraoperative transesophageal echocardiogra-
phy (n  3), intraoperative arteriography (n  1), or postmortem autopsy (n  1).
Conclusions: rAAD is a lethal early complication of TEVAR, which may be more common when treating dissection, with
devices utilizing proximal bare springs or barbs for fixation, with native zone 0 proximal landing zone and with ascending
aortic diameter >4 cm. Combinations of these risk factors may be particularly high risk. Intraoperative imaging
assessment of the ascending aorta should be conducted following TEVAR to avoid under-recognition. National database
reporting of this complication is needed to ensure safety and proper application of emerging TEVAR technology. (J Vasc
Surg 2012;55:1255-62.)
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MSince reports of encouraging early results in the 1990s,
thoracic endovascular aortic repair (TEVAR) has been in-
creasingly utilized as a treatment option for a variety of
aortic pathologies.1-3 In 2005, the United States Food and
Drug Administration (FDA) approved the first endopros-
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doi:10.1016/j.jvs.2011.11.063hesis for thoracic aortic aneurysm treatment.4 While care-
ully conducted randomized controlled trials provide essen-
ial information for determination of safety and efficacy of
merging medical products and techniques, medical prod-
ct trials are carried out in highly controlled environments
or prescribed and limited periods of time. In many ways,
edical product data gathered through randomized con-
rolled trials is a prologue to the ultimate test of the device
y clinicians in everyday practice.5
As clinical databases and registries accumulate data,
ncommon complications of medical products such as
EVAR devices may begin to be recognized and charac-
erized, especially when used for indications outside
DA-specified indications. Several reports have identi-
ed retrograde ascending aortic dissection (rAAD) as a
otentially lethal complication of TEVAR.6,7 As such,
he objective of the present study was to examine the
ncidence, etiology, treatment, and outcome of rAAD as
complication following TEVAR using a detailed pro-
pective clinical database.
ETHODS
Data sources. The Duke Thoracic Aortic Surgery Da-
abase is a prospectively maintained, comprehensive clinical
1255
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May 20121256 Williams et alregistry of all patients who have undergone a thoracic aortic
procedure at Duke University Medical Center (Durham,
NC) since 2005. The present study included all patients who
underwent TEVAR between March 23, 2005 (date of FDA
approval of the first available thoracic device in the U.S.) and
May 2010. No patients were excluded. The Duke Thoracic
Aortic Surgery Database provided baseline characteristics,
clinical variables, and surgical procedure details. Review of
individual medical records was undertaken to complete any
missing data points prior to analysis. This study was ap-
proved by the Duke University Institutional Review Board
and the need for individual patient consent was waived.
All presented aortic diameter measurements were ob-
tained using the centerline method with a TeraRecon
Aquarius iNtuition workstation (TeraRecon Inc, San Ma-
teo, Calif). Device oversizing was calculated according to
the diameter from the adventitia to adventitia of the prox-
imal landing zone on computed tomography angiography
(CTA). Classification of proximal stent graft landing zone
within the thoracic aorta was performed using the classifi-
cation scheme proposed by Ishimaru et al.8 In addition,
patients undergoing prior ascending aortic  arch replace-
ment with Dacron zone 0 proximal landing zone were
discriminated from those with native aorta zone 0 landing
zone and excluded, given the impossibility for the former to
suffer rAAD.
Comorbidities were defined using standard definitions
according to the Society of Thoracic Surgeons Adult Car-
diac SurgeryDatabase.9 All follow-upwas done at theDuke
Center for Aortic Surgery. Details regarding the follow-up
protocol as performed at our institution have been de-
scribed elsewhere2 and included clinical examination and
computed tomography angiography (CTA) at 1, 6, and 12
months postoperatively and annually thereafter. All proce-
dural outcomes and complications were prospectively re-
corded. Data are presented in accordance with the “Re-
porting Standards for Endovascular Aortic Aneurysm
Repair” of the Ad Hoc Committee for Standardized
Reporting Practices in Vascular Surgery of the Society
for Vascular Surgery/American Association for Vascular
Table I. Summary of the patients suffering acute retrograd
grafting
Patient # Age Gender Race
Initial
operative
indication Device
Pro
lan
z
1 69 F White Aneurysm TAG
2 60 M Black Dissection TX2
3 46 M White Dissection TX2
4 79 F Asian Aneurysm Talent
5 55 F White Dissection Talent
6 56 M White Dissection TAG
AA, Ascending aorta; BAV, congenital bicuspid aortic valve; MFS, Marfan sSurgery.10 sConduct of procedures. TEVAR patient selection
nd techniques of device delivery and deployment have
een described previously.2,11 All three thoracic stent
rafts, FDA-approved during the period of the study, were
tilized. These included: Gore TAG (W. L. Gore and
ssociates, Flagstaff, Ariz [n  206; 66.7%]), Medtronic
alent (Medtronic, Inc, Santa Rosa, Calif [n  43;
3.9%]), and Zenith TX2 (Cook Medical Inc, Blooming-
on, Ind [n  57; 18.4%]). Indications for each TEVAR
rocedure were classified as degenerative aneurysm (includ-
ng penetrating atherosclerotic ulcers), acute and chronic
issection, or acute blunt traumatic aortic injury (transec-
ion). As previously described,12,13 intraoperative trans-
sophageal echocardiography (TEE) is utilized routinely in
ll TEVAR cases, with intravascular ultrasound (IVUS)
sed in all aortic dissection cases and selectively in others.
Statistical analysis. Patient and operative characteris-
ics were summarized (Tables I and II) with categorical
ariables presented as percentages and continuous variables
s means and standard deviations unless otherwise stated.
or comparisons, the Wilcoxon rank-sum test was used for
ontinuous variables and the Fisher’s exact test for categor-
cal variables, with an alternative hypothesis that the rates
cross columns were not equal. All statistical analyses were
erformed using SAS version 9.1.3 (SAS Institute, Cary,
C) and Graphpad software (Graphpad Software, Inc, La
olla, Calif).
ESULTS
Patient demographic and operative characteristics.
uring the study period, 309 consecutive TEVAR proce-
ures were performed at a single referral institution; six
atients suffered rAAD, for an incidence of 1.9%. The
verall mean age of the study group was 64 years. Females
omprised 38% of the patients overall, 40% were of races
ther than white, 49% were smokers, 77% suffered hyper-
ension, and 20% were diabetics.
Table I details the clinical characteristics of the six
atients suffering rAAD. All had proximal landing zones in
he ascending aorta and/or arch (zones 0-2). Patient #1
pe A dissection following thoracic endovascular stent
Presumed rAAD etiology Comments
Procedure related; catheter/power
injection injury
Stent-graft induced 4.0 cm AA
Stent-graft induced BAV; 4.0 cm AA
Stent-graft induced; misaligned
deployment
4.0 cm AA
Stent-graft induced; misaligned
deployment
MFS
Presumed partial occlusion clamp injury
during arch debranching
4.0 cm AA
me; rAAD, retrograde ascending aortic dissection.e ty
ximal
ding
one
2
2
2
0
2
0uffered rAAD as a result of malposition of a pigtail catheter
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Volume 55, Number 5 Williams et al 1257ith the tip abutting the aortic wall during a power contrast
njection; the dissection did not appear to be device-
elated. Patients #2 and #3 both had device-related dissec-
ions based on findings at surgical repair (primary tear
mmediately adjacent to proximal end of endograft). Of
ote, both had dilated (4.0 cm) ascending aortas, with
atient #3 also having a congenital bicuspid aortic valve,
hich is known to be associated with aortopathy of the
scending aorta in over half of patients.14 Patients #4 and
5 likewise both had device-related dissections with direct
rterial wall injury from misaligned deployment15 utilizing
he prior-generation Talent device. Patient #5 also had
arfan syndrome but was considered a poor candidate for
onventional open repair of her complicated acute type B
issection, given prior pulmonary resection for lung cancer
nd severe chronic obstructive pulmonary disease requiring
ome oxygen. Patient #6 had rAAD originating adjacent to
he origin of the inflow anastomosis of the bypass graft used
or arch debranching during off-pump hybrid arch repair.
his delayed dissection (postoperative day 3) was presum-
bly related to aortic wall injury from partial cross-clamp
pplication and did not appear to be device-related based
n autopsy findings.
Table II describes patient and operative variables strat-
fied by whether or not patients suffered a post-TEVAR
able II. Continued
ariablea
Non-rAAD
(n  303)
rAAD
(n  6) P value
one 1 4.6 (14) 0.0 (0)
one 2 35.0 (106) 66.7 (4)
one 3 9.6 (29) 0.0 (0)
one 4 39.9 (121) 0.0 (0)
se of cardiopulmonary
bypass among zone 0
cases
27.3 (9/33) 0.0. (0/2) .496
onnective tissue
disorderd with landing
zone(s) in native aorta
0.33 (1) 16.7 (1) .039
issection TEVAR
indication and
ascending aorta 4 cm
8.3 (25) 50.0 (3) .011
issection TEVAR
indication and zone 0
proximal landing zone
3.9 (12) 16.7 (1) .229
scending aorta 4 cm
and native zone 0
proximal landing zone
1.7 (5) 33.3 (2) .006
issection TEVAR
indication, ascending
aorta 4 cm, and zone
0 proximal landing
zone
0.33 (1) 16.7 (1) .039
AAD, Retrograde ascending aortic dissection; TEVAR, thoracic endovas-
ular aneurysm repair.
Categorical data are given as % (n). Continuous data are given as mean 
tandard deviation.
Includes overstenting of the left subclavian artery.
Classification system of Ishimaru et al.8
Both Marfan syndrome patients.Table II. Patient demographic and operative
characteristics
Variablea
Non-rAAD
(n  303)
rAAD
(n  6) P value
Age 64.1  14.5 61.8  12.7 .895
Female 40.0 (113) 50.0 (3) .416
Race .849
White 60.1 (182) 66.7 (4)
Black 33.3 (101) 16.7 (1)
Other 6.6 (20) 16.7 (1)
Body mass index 27.7  5.9 24.9  3.0 .272
American Society of
Anesthesiologist class
3.5  0.5 3.6  0.5 .670
Steroid use preoperatively 2.6 (8) 0.0 (0) .676
Active or recent smoker 49.5 (150) 40.0 (2) .537
Hypertension 77.2 (234) 80.0 (4) .997
Diabetes mellitus 20.1 (61) 40.0 (2) .729
Peripheral vascular disease 19.8 (60) 0.0 (0) .485
Congestive heart failure 11.6 (35) 40.0 (2) .132
History of stroke 10.9 (33) 0.0 (0) .373
Preoperative creatinine 1.4  1.2 1.1  0.3 .380
Preoperative hemoglobin 12.4  2.1 13.5  1.6 .237
Prior aortic surgery 41.2 (125) 33.3 (2) 1.00
Initial operative
indication
.082
Aneurysm 65.3 (198) 33.3 (2)
Dissection 28.7 (87) 66.7 (4)
Transection 5.9 (18) 0.0 (0)
Index case status .709
Elective 62.7 (190) 66.7 (4)
Urgent 24.1 (73) 33.3 (2)
Emergent 13.2 (40) 0.0 (0)
Bovine arch 13.5 (41) 33.3 (2) .197
Aortic wall calcification .746
None 33.3 (101) 33.3 (2)
Mild 53.8 (163) 50.0 (3)
Moderate 10.2 (31) 16.7 (1)
Severe 2.6 (8) 0.0 (0)
Diameter of most
proximal stent graft,
mm
34  5 35  7 .596
Maximum aortic
diameter, cm
5.8  1.6 6.0  1.2 .995
Tubular ascending aortic
diameter 4 cm
26.1 (79) 66.7 (4) .047
Stent graft device used .189
TAG (Gore) 67.3 (204) 33.3 (2)
Talent (Medtronic) 13.5 (41) 33.3 (2)
Zenith TX2 (Cook) 17.5 (53) 33.3 (2)
Other 1.7 (5) 0.0 (0)
Design of most proximal
stent graft
.197
Free-flow bare spring 13.5 (41) 33.3 (2)
Membrane-covered 86.5 (262) 66.7 (4)
Deployment direction .060
Proximal to distal 72.0 (218) 33.3 (2)
Distal to proximal 28.0 (85) 66.7 (4)
Over-stenting of arch
vessel(s)b
50.5 (153) 100.0 (6) .030
Device oversizing, %
(range)
9.0 (0-20) 9.2 (0-23) .488
Total number of devices
implanted
1.9  1.0 1.7  0.52 .626
Proximal landing zonec .090
All zone 0 10.9 (33) 33.3 (2)
Native zone 0 aorta (ie, 8.9 (27) 33.3 (2)AAD. Patients with and without the rAAD complication
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May 20121258 Williams et alwere generally similar with regard to baseline demographic
characteristics, including age, gender, body mass index,
steroid use, smoking status, hypertension, diabetes melli-
tus, peripheral vascular disease, previous aortic surgery, case
status, presence of aortic wall calcification, and other perti-
nent variables.
A bovine arch was present in 14% of all patients, includ-
ing 33% (2/6) of the rAAD cases. Compared with patients
not suffering retrograde dissection, a significantly greater
number of patients suffering rAAD had an ascending aortic
diameter 4.0 cm (67% vs 26%, respectively; P  .047;
Table II). Device oversizing was found to be congruent
between the rAAD and non-rAAD groups, with 9.0%
(range, 0%-20%) oversizing in the rAAD group and 9.2%
(range, 0%-23%) oversizing in the non-rAAD group.
While free-flow bare spring proximal stent graft design
accounted for only 14% of the non-rAAD cases, one-third
(2/6) of the rAAD cases occurred following deployment of
devices with this design (P .20). As noted in Table I, both
of the retrograde ascending dissections with free-flow prox-
imal bare springs appeared to be related to misaligned
deployment with direct aortic wall injury by the bare
springs. Deployment direction was distal to proximal in
only 28% of non-rAAD cases but 67% of rAAD cases (P 
.06). As noted above, overstenting of at least one arch
vessel was performed in 100% of rAAD cases compared with
51% of non-rAAD cases (P  .03). Specifically, proximal
landing zone among the rAAD cases was 33% in native (ie,
not Dacron) zone 0 and 67% in zone 2; this was in contrast
to 11% total zone 0 (with 9% native zone 0), 5% zone 1, and
35% zone 2 among non-rAAD cases (P  .09; Table II).
Only two patients in the entire series had landing zone(s)
(Table II) within native connective tissue disorder aorta
(both patients with Marfan syndrome), and one suffered
rAAD.
Incidence by device, indication, ascending aortic
diameter, and proximal landing zone. The incidence of
rAAD following cases utilizing the TAG device was 1.0%
(2/206) compared with 4.7% (2/43) for the Talent device
and 3.6% (2/55) for Zenith TX2 (P.316; Table III). This
low incidence of rAAD for TAG was in spite of the fact that
it was the device used most frequently among dissection
cases (the aortic pathology with the highest incidence of
rAAD), with 76% of dissection cases treated with this
device. As noted in Table I, neither of the two rAAD cases
with the TAG device appeared to be device-related. Among
those patients treated for an FDA-approved indication,2
the incidence of rAAD was 0.7% (1/150) versus 3.1%
(5/159) for those patients treated off-label (P  .21).
Specifically, rAAD was more commonly observed after
TEVAR for dissection versus other indications (P  .08).
Table III reveals an incidence for rAAD of 1.0% (2/200)
for TEVAR treating aortic aneurysm, 4.4% (4/91) for
acute or chronic dissection, and 0% (0/18) for acute blunt
traumatic aortic injury (transection). For those patients
undergoing hybrid arch repair with zone 0-1 proximal
landing zone (n  49; Table II), the incidence was 4.1%
(2/49). With a proximal landing zone in native (ie, non- Tacron) ascending aorta (zone 0), the incidence of rAAD
as 6.9% (2/29) compared with 1.4% (4/280) for all other
roximal landing zones (P  .10; Table III). rAAD inci-
ence was observed to be higher among patients with an
scending aortic diameter 4.0 cm (4.8%) versus an inci-
ence of only 0.9% for ascending diameter 4.0 cm (P 
047). The incidence of rAAD was seen to increase mark-
dly with combinations of higher-risk scenarios (Table III).
ith a dissection, TEVAR indication, and an ascending
ortic diameter4.0 cm, the incidence was 10.7% (3/28).
urther increase was seen with native zone 0 proximal
anding zone and an ascending aortic diameter 4.0 cm
25.0%; 2/8).
Detection and management. Table IV summarizes
he details of the detection and management of the six
AAD cases in this series of 309 TEVAR procedures. All
ases were identified in the perioperative period (range, 0-6
ays). New-onset chest pain and hypotension on postoper-
tive day 6 prompted CTA for definitive diagnosis in one
atient (#2; Tables I and IV); this patient had a normal
ntraoperative TEE at the completion of the procedure
Fig). Four rAAD complications were identified intraoper-
tively, with definitive diagnosis made by TEE in one,
VUS plus TEE in two, and the fourth identified initially by
rteriography with TEE confirmation. All identified rAAD
ases were treated with emergent open repair. Overall
ortality was 33% (2/6) among the patients suffering
AAD. The first death occurred in a 79-year-old female (#4;
able III. Incidence of rAAD according to device
tilized, initial aortic pathology necessitating TEVAR,
ocation of proximal landing zone, and ascending aortic
iameter
ariable
Incidence of rAAD
complication P value
EVAR device used .316
AG (Gore) 1.0% (2/206)
alent (Medtronic) 4.7% (2/43)
enith TX2 (Cook) 3.6% (2/55)
ther 0% (0/5)
nitial aortic pathology necessitating
TEVAR
.082
neurysm 1.0% (2/200)
issection 4.4% (4/91)
raumatic transection 0% (0/18)
roximal landing zone .101
ative ascending aorta (zone 0)a 6.9% (2/29)
ll other landing zones 1.4% (4/280)
scending aortic diameter .047
4.0 cm 4.8% (4/83)
4.0 cm 0.9% (2/226)
issection pathology and ascending
aorta 4 cm
10.7% (3/28)
ative zone 0 proximal landing zone
and ascending aorta 4 cm
25.0% (2/8)
AAD, Retrograde ascending aortic dissection; TEVAR, thoracic endovas-
ular aortic repair.
Classification system of Ishimaru et al.8ables I and IV) undergoing hybrid arch repair with native
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 5 Williams et al 1259Table IV. Detection and management of the patients suffering acute rAAD following thoracic endovascular aortic
repair
Patient #
Time of
discovery Signs/symptoms
Definitive
diagnosis Treatment Outcome
1 Intraoperative Abnormal intraoperative TEE TEE Emergent open repair Uneventful recovery
2 POD 6 Chest pain, hypotension CTA Emergent open repair Uneventful recovery
3 Intraoperative Abnormal IVUS  TEE IVUS  TEE Emergent open repair Uneventful recovery
4 Intraoperative Hemodynamic instability Arteriogram Emergent open repair Intraoperative death
5 Intraoperative Abnormal arteriogram IVUS  TEE Emergent open repair Uneventful recovery
6 POD 3 Hemodynamic collapse Autopsy None Death on inpatient ward
CTA, Computed tomography angiography; IVUS, intravascular ultrasound; POD, postoperative day; rAAD, retrograde ascending aortic dissection; TEE,
transesophageal echocardiogram.Fig. Preoperative computed tomography angiography (CTA) in patient undergoing thoracic endografting (TEVAR)
for chronic type B dissection with aneurysm who suffered postoperative retrograde ascending aortic dissection (rAAD).
Note dilated ascending aorta measuring 4.5 cm (A); Normal transesophageal echocardiogram (TEE) at the completion
of TEVAR procedure (B); CTA obtained after new-onset chest pain and hypotension on postoperative day 6 revealing
acute rAAD (C); Intraoperative TEE showing rAAD at the time of open repair (D).
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May 20121260 Williams et alzone 0 proximal landing zone. The patient died in the
operating room due to refractory right heart failure, despite
technically successful open repair. The second death oc-
curred in a 56-year-old man (#6; Tables I and IV) with a
distal arch/proximal descending aneurysm secondary to
chronic type B dissection. He underwent uncomplicated
off-pump hybrid arch repair with native zone 0 proximal
landing zone and was out on the routine inpatient ward on
postoperative day 3 when he suffered acute hemodynamic
collapse and could not be resuscitated; the diagnosis of
rAAD was made at autopsy.
DISCUSSION
In this observational study of consecutive U.S. patients
undergoing TEVAR fromMarch 2005 (date of initial FDA
approval) through May 2010, we identified six cases of
rAAD, for an overall incidence of 1.9% for this complica-
tion. All of the cases occurred with proximal landing zone
in the ascending aorta and/or arch (zones 0-2) and were
identified in the perioperative period (range, 0-6 days);
30-day/in-hospital mortality was 33%. The incidence also
appeared higher when performing TEVAR for dissection
(4.4%), in the setting of an ascending aortic diameter4.0
cm (4.8%), and when utilizing native ascending aorta (zone
0) for the proximal landing zone (6.9%). Incremental risk
was incurred with combinations of these latter three scenar-
ios with an incidence of 10.7% following TEVAR for dis-
section in the setting of an ascending aortic diameter 4.0
cm and 25% for native zone 0 proximal landing zone
measuring 4.0 cm (Table III).
The risk of iatrogenic dissection of the ascending aorta
after TEVAR has only recently been acknowledged as ex-
perience has grown and the clinical applications of TEVAR
techniques have expanded.6,7,16-18 For example, hybrid
arch repair was not employed in the initial TEVAR clinical
trials. The present findings build on other published reports
which have identified rAAD as a potential complication of
TEVAR for all indications and have estimated the risk of
this complication to range between 1.3% and 6.8%.6,7,17,19
Further, the study confirms the lethality of this complica-
tion with an overall 30-day/in-hospital mortality rate of
33%; for patients undergoing surgical repair, the mortality
was 20%. Although less than the nearly 50% mortality for
acute dissection developing as a complication of cardiac
surgery,20 this post-TEVAR rAAD mortality rate remains
quite significant and higher than that for spontaneously
occurring acute type A dissection.21
Although we generally avoid landing endografts in
native aorta in patients with connective tissue disorders,22
one of six (16.7%) rAAD patients in the present series had a
landing zone in native Marfan aorta versus an incidence of
0.33% (1/303) in the non-rAAD cohort. This finding is
similar to those of prior studies by the European Registry
on Endovascular Aortic Repair Complications by Egg-
ebrecht et al6 and a Chinese study by Dong et al.7 The
European Registry captured 48 TEVAR cases in Marfan
patients (rAAD incidence 8.3%), and in the Dong et al
study, 27% (3/11) of rAAD cases were patients with Mar- dan syndrome.6,7 Overall, these findings continue to sup-
ort the avoidance of TEVAR in the connective tissue
opulation except in select circumstances.
The rAAD incidence of 4.4% in our series following
EVAR for dissection is consistent with that reported by
ong et al (2.5%),7 but lower than that reported by Neu-
auser and colleagues (17.8%).23 In contrast to the Euro-
ean experience, we did not identify any cases of retrograde
ype A dissections in follow-up. We attribute this to the use
f intraoperative TEE, which likely catches the complica-
ion early. Eggebrecht et al, from the European Registry,
ound that 40 of 48 (83%) cases of rAAD following TEVAR
nderwent the initial procedure for treatment of either
cute or chronic aortic dissection.6 A higher rAAD inci-
ence with dissection is biologically intuitive, given the
riability of the aortic wall of patients suffering spontaneous
issection.
A recent study from the International Registry of
cute Aortic Dissection found that an ascending aortic
iameter 4.0 cm was common (40.2%) in patients with
cute type B aortic dissection, although there was no
ifference in overall mortality or cause of death between
hose with small and large ascending aortas.24 Interest-
ngly, those with smaller proximal aortas were more likely
o receive endovascular therapy, while those with larger
scending aortas more frequently underwent open surgical
epair to include the proximal aorta. This paradigm is
upported by the current study, which found a significant
isk (10.7%) of rAAD following TEVAR in patients with an
scending aortic diameter 4.0 cm treated for a dissection
ndication. This dilated ascending aorta is likely a marker of
iffuse aortic disease and inherent weakness of the diseased
ortic wall.
The potential etiologies of rAAD following TEVAR
ay be classified as procedure-related, device-related, and
isease progression. Excessive radial force from oversizing
f the stent graft prosthesis to 20% relative to the diam-
ter of the aorta has been proposed by Kpodonu et al as a
otential causative factor for rAAD following TEVAR.17
podonu et al examined only the Gore TAG endoprosthe-
is and found that potentially excessive oversizing of the
ndograft occurred in three of seven (43%) rAAD pa-
ients.17 This did not, by contrast, appear to be a causative
actor in the present series, with average device oversizing
f approximately 9% (range, 0%-23%) for those patients
oth with and without rAAD.
The present report suggests that rAAD is more com-
on (4.7%) with devices using a free-flow bare spring
roximal stent graft design. This finding supports prior
ork suggesting proximal bare springs may confer an in-
reased risk of rAAD.7,17,25 In the European Registry study
y Eggebrecht et al, devices with proximal bare springs
ere used in 27 of 29 (93%) patients suffering TEVAR-
elated rAAD.6 It should be noted, however, that in our
eries both retrograde dissections with free-flow bare spring
evices appeared to result from misaligned deployment
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Volume 55, Number 5 Williams et al 1261with direct aortic wall injury by the bare springs. Since the
time of this report, the new Talent with Captivia device has
received FDA approval26 and avoids the occurrence of
misaligned deployment problematic in the current series.
As such, future work will be required to assess whether this
modification results in a decrease in rAAD rates.
Dynamic interactions between the endoprosthesis and
the native aorta may also play a role in rAAD development,
particularly in cases with native ascending aorta (zone 0)
proximal landing zone. Radial expansion-contraction and
translational wall motion are most pronounced for zone 0
aortic endografting.18,27 This may explain the increased
incidence (6.9%) of rAAD seen with zone 0 proximal
landing zone in the current series. Moreover, successful
development of more compliant endoprostheses with im-
proved flexibility for use in cases of dissection, zone 0
proximal landing zone, and other high-risk groups may
help reduce the incidence of post-TEVAR rAAD.25
Other investigators have proposed balloon dilation of
the stent graft to be associated with rAAD following TE-
VAR.17 Intimal tears could be caused by applying the radial
force of balloon angioplasty to devices with proximal bare
springs or barbs for proximal fixation.17 Given that the only
device routinely balloon-molded postdeployment (TAG)
had the lowest incidence of rAAD, as well as the fact that
none of the rAADs occurring with non-TAG devices had
postdeployment balloon molding (data not shown), this
would not appear to be a contributing factor in the present
report.
The role of IVUS and TEE in facilitating early detec-
tion of rAAD following TEVAR remains unproven,28 but
in our series allowed initial detection of three of the four
intraoperatively occurring retrograde dissections; further,
TEE was confirmatory in the fourth case (#4, Table IV)
initially seen on angiography. Given these findings, we
consider completion imaging assessment of the ascending
aorta with TEE and/or IVUS to be mandatory following
all TEVAR cases. While the natural history of iatrogenic
rAAD is not established,29,30 availability of surgeons for
immediate open repair of rAAD should likewise be manda-
tory in centers performing TEVAR, given that the optimal
treatment appears to be prompt surgical repair.
Limitations. This study was observational, and the
findings presented represent hypothesis generation. In ad-
dition, the overall low prevalence of the rAAD complica-
tion led to wide confidence limits for point estimates and
statistical comparisons. While all patients in this series were
followed at the Duke Center for Aortic Surgery, the possi-
bility remains that late rAAD complications may have oc-
curred unrecognized in patients suffering late death. Gen-
eralizability of this study is limited by the single-center
results. However, this is among the largestU.S. data available,
and the performance of all procedures at one center by a single
team eliminates many of the center-level and provider-level
confounders encountered when aggregating uncommon
complications across diverse locations.ONCLUSIONS
These data indicate that rAAD is a serious complication
f an expanding treatment strategy for pathology of the
horacic aorta, especially when utilized for pathology in the
ortic arch. This morbid complication warrants careful
igilance for trends with the use of new devices and tech-
iques as well as careful surveillance of individual patients.
AAD may be more common when treating dissection,
ith devices utilizing proximal bare springs or barbs for
xation, with native zone 0 proximal landing zone, and
ith an ascending aortic diameter4 cm. The risk appears
specially high with combinations of a dissection indica-
ion, dilated ascending aorta, and/or native zone 0
roximal landing zone. Intraoperative imaging assess-
ent of the ascending aorta should be considered man-
atory following TEVAR to avoid under-recognition of
his often lethal complication. National database report-
ng of this complication, such as is now possible through
he Society of Thoracic Surgeons Adult Cardiac Surgery
atabase (version 2.73),9 is needed to ensure safety and
roper application of emerging TEVAR technology.
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